Tag

Bluebird Bio

All articles tagged with #bluebird bio

biotechnology1 year ago•1 min saved

"Advancements in Bluebird Gene Therapies, Vertex's Pain Drug, and ADC FOMO"

Bluebird Bio's focus on selling gene therapies, such as Lyfgenia for sickle cell disease, Zynteglo for beta thalassemia, and Skysona for cerebral adrenoleukodystrophy, without other marketed products, makes it a unique player in the gene therapy market, raising questions about the profitability of gene therapies as a business. The company's approach and success over the next year may provide insights into the potential for gene therapies to become a profitable venture.

via STAT|

#biotech #biotechnology #bluebird-bio

business2 years ago•0 min saved

Bluebird Bio's Sickle Cell Gene Therapy Faces Challenges Amid Approval

Bluebird Bio's gene therapy for sickle cell disease, Lyfgenia, was approved but mispriced at $3.1 million, making it significantly more expensive than Vertex Pharmaceutical's competing treatment, Casgevy, which was priced at $2.2 million. Additionally, Lyfgenia carries a "black box" safety warning, requiring regular blood monitoring for cancer risk, while Casgevy does not. These strategic blunders could jeopardize Bluebird's independence and survival, potentially leading to a company sale.

via STAT|

#bluebird-bio #business #financial-struggles

healthcare2 years ago•0 min saved

"Lyfgenia FDA Approval Sparks Competition in Sickle Cell Treatment Market"

The FDA's approval of two gene therapies for sickle cell disease paves the way for competition between Bluebird Bio's Lyfgenia and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy. While Casgevy has the advantage of being a CRISPR-based therapy, some physicians and patients may prefer the lentiviral vector technology behind Lyfgenia, despite the added risk of blood cancer.

via STAT|

#bluebird-bio #crispr-therapeutics #gene-therapy

health2 years ago•3 min saved

FDA Approves Game-Changing Gene Therapies for Sickle Cell Disease

The U.S. FDA has granted approval for two gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease (SCD). Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first treatment in the U.S. to utilize CRISPR gene editing technology. SCD is an inherited blood disorder that affects around 100,000 people in the U.S., primarily Black individuals. Both therapies have shown promising results in reducing painful episodes in clinical trials. Casgevy has a list price of $2.2 million, while Lyfgenia is priced at $3.1 million. However, Lyfgenia's higher price and safety warning may impact its sales compared to Casgevy.

via Reuters|

#bluebird-bio #crispr #fda

business2 years ago•1 min saved

"Bluebird Bio spinout, 2Seventy Bio, undergoes restructuring and layoffs as cell therapy struggles"

Biotech spinout 2Seventy Bio, which was formed from the split of Bluebird Bio, announced significant cost cuts including a 40% reduction in its workforce and reduced funding for certain drug candidates. The company's CEO, Nick Leschly, will be departing as part of the restructuring. The cuts are aimed at extending the company's cash runway into 2026.

via STAT|

#2seventy-bio #bluebird-bio #business

health2 years ago•10 min saved

Gene-based therapies show promise in transforming sickle cell disease.

Two gene-based treatments for sickle cell disease, a genetic blood disorder that mostly affects people of color, could be approved by the FDA late this year or early in 2024. The treatments, a gene therapy from Bluebird Bio and a gene-editing treatment by a partnership between Vertex Pharmaceuticals and CRISPR Therapeutics, have shown promising results in clinical trials, with some scientists calling them "potentially curative." However, concerns remain about the high cost of the treatments, which are expected to cost at least $1 million to $2 million each, and the durability of their benefits.

via The Boston Globe|

#bluebird-bio #crispr #gene-based-therapies